Reviews Refacto


No reviews yet.

Refacto Drug Description
ReFacto®
Antihemophilic Factor, Recombinant
DRUG DESCRIPTION
ReFacto® Antihemophilic Factor (Recombinant) is a purified protein produced
by recombinant DNA technology for use in therapy of factor VIII deficiency.
ReFacto is a glycoprotein with an approximate molecular mass of 170 kDa consisting
of 1438 amino acids. It has an amino acid sequence that is comparable to the
90 + 80 kDa form of factor VIII, and post-translational modifications that are
similar to those of the plasma-derived molecule. ReFacto has in vitro
functional characteristics comparable to those of endogenous factor VIII.
ReFacto is produced by a genetically engineered Chinese hamster ovary (CHO) cell line. The CHO cell line secretes B-domain deleted recombinant factor VIII into a defined cell culture medium that contains human serum albumin and recombinant insulin, but does not contain any proteins derived from animal sources. The protein is purified by a chromatography purification process that yields a high-purity, active product. The potency expressed in international units (IU) is determined using the European Pharmacopoeial chromogenic assay against the WHO standard. The specific activity of ReFacto is 9110-13700 IU per milligram of protein. ReFacto is not purified from human blood and contains no preservatives or added human or animal components in the final formulation.
ReFacto is formulated as a sterile, nonpyrogenic, lyophilized powder preparation for intravenous (IV) injection. It is available in single-use vials containing the labeled amount of factor VIII activity (IU). Each vial contains nominally 250, 500, 1000 or 2000 IU of ReFacto per vial. The formulated product is a clear colorless solution upon reconstitution and contains sodium chloride, sucrose, L-histidine, calcium chloride, and polysorbate 80.
Last reviewed on RxList: 2/19/2009




Refacto Drug Description
ReFacto®
Antihemophilic Factor, Recombinant
DRUG DESCRIPTION
ReFacto® Antihemophilic Factor (Recombinant) is a purified protein produced
by recombinant DNA technology for use in therapy of factor VIII deficiency.
ReFacto is a glycoprotein with an approximate molecular mass of 170 kDa consisting
of 1438 amino acids. It has an amino acid sequence that is comparable to the
90 + 80 kDa form of factor VIII, and post-translational modifications that are
similar to those of the plasma-derived molecule. ReFacto has in vitro
functional characteristics comparable to those of endogenous factor VIII.
ReFacto is produced by a genetically engineered Chinese hamster ovary (CHO) cell line. The CHO cell line secretes B-domain deleted recombinant factor VIII into a defined cell culture medium that contains human serum albumin and recombinant insulin, but does not contain any proteins derived from animal sources. The protein is purified by a chromatography purification process that yields a high-purity, active product. The potency expressed in international units (IU) is determined using the European Pharmacopoeial chromogenic assay against the WHO standard. The specific activity of ReFacto is 9110-13700 IU per milligram of protein. ReFacto is not purified from human blood and contains no preservatives or added human or animal components in the final formulation.
ReFacto is formulated as a sterile, nonpyrogenic, lyophilized powder preparation for intravenous (IV) injection. It is available in single-use vials containing the labeled amount of factor VIII activity (IU). Each vial contains nominally 250, 500, 1000 or 2000 IU of ReFacto per vial. The formulated product is a clear colorless solution upon reconstitution and contains sodium chloride, sucrose, L-histidine, calcium chloride, and polysorbate 80.
Last reviewed on RxList: 2/19/2009




Refacto Drug Description
ReFacto®
Antihemophilic Factor, Recombinant
DRUG DESCRIPTION
ReFacto® Antihemophilic Factor (Recombinant) is a purified protein produced
by recombinant DNA technology for use in therapy of factor VIII deficiency.
ReFacto is a glycoprotein with an approximate molecular mass of 170 kDa consisting
of 1438 amino acids. It has an amino acid sequence that is comparable to the
90 + 80 kDa form of factor VIII, and post-translational modifications that are
similar to those of the plasma-derived molecule. ReFacto has in vitro
functional characteristics comparable to those of endogenous factor VIII.
ReFacto is produced by a genetically engineered Chinese hamster ovary (CHO) cell line. The CHO cell line secretes B-domain deleted recombinant factor VIII into a defined cell culture medium that contains human serum albumin and recombinant insulin, but does not contain any proteins derived from animal sources. The protein is purified by a chromatography purification process that yields a high-purity, active product. The potency expressed in international units (IU) is determined using the European Pharmacopoeial chromogenic assay against the WHO standard. The specific activity of ReFacto is 9110-13700 IU per milligram of protein. ReFacto is not purified from human blood and contains no preservatives or added human or animal components in the final formulation.
ReFacto is formulated as a sterile, nonpyrogenic, lyophilized powder preparation for intravenous (IV) injection. It is available in single-use vials containing the labeled amount of factor VIII activity (IU). Each vial contains nominally 250, 500, 1000 or 2000 IU of ReFacto per vial. The formulated product is a clear colorless solution upon reconstitution and contains sodium chloride, sucrose, L-histidine, calcium chloride, and polysorbate 80.
Last reviewed on RxList: 2/19/2009




Refacto Drug Description
ReFacto®
Antihemophilic Factor, Recombinant
DRUG DESCRIPTION
ReFacto® Antihemophilic Factor (Recombinant) is a purified protein produced
by recombinant DNA technology for use in therapy of factor VIII deficiency.
ReFacto is a glycoprotein with an approximate molecular mass of 170 kDa consisting
of 1438 amino acids. It has an amino acid sequence that is comparable to the
90 + 80 kDa form of factor VIII, and post-translational modifications that are
similar to those of the plasma-derived molecule. ReFacto has in vitro
functional characteristics comparable to those of endogenous factor VIII.
ReFacto is produced by a genetically engineered Chinese hamster ovary (CHO) cell line. The CHO cell line secretes B-domain deleted recombinant factor VIII into a defined cell culture medium that contains human serum albumin and recombinant insulin, but does not contain any proteins derived from animal sources. The protein is purified by a chromatography purification process that yields a high-purity, active product. The potency expressed in international units (IU) is determined using the European Pharmacopoeial chromogenic assay against the WHO standard. The specific activity of ReFacto is 9110-13700 IU per milligram of protein. ReFacto is not purified from human blood and contains no preservatives or added human or animal components in the final formulation.
ReFacto is formulated as a sterile, nonpyrogenic, lyophilized powder preparation for intravenous (IV) injection. It is available in single-use vials containing the labeled amount of factor VIII activity (IU). Each vial contains nominally 250, 500, 1000 or 2000 IU of ReFacto per vial. The formulated product is a clear colorless solution upon reconstitution and contains sodium chloride, sucrose, L-histidine, calcium chloride, and polysorbate 80.
Last reviewed on RxList: 2/19/2009




Refacto Drug Description
ReFacto®
Antihemophilic Factor, Recombinant
DRUG DESCRIPTION
ReFacto® Antihemophilic Factor (Recombinant) is a purified protein produced
by recombinant DNA technology for use in therapy of factor VIII deficiency.
ReFacto is a glycoprotein with an approximate molecular mass of 170 kDa consisting
of 1438 amino acids. It has an amino acid sequence that is comparable to the
90 + 80 kDa form of factor VIII, and post-translational modifications that are
similar to those of the plasma-derived molecule. ReFacto has in vitro
functional characteristics comparable to those of endogenous factor VIII.
ReFacto is produced by a genetically engineered Chinese hamster ovary (CHO) cell line. The CHO cell line secretes B-domain deleted recombinant factor VIII into a defined cell culture medium that contains human serum albumin and recombinant insulin, but does not contain any proteins derived from animal sources. The protein is purified by a chromatography purification process that yields a high-purity, active product. The potency expressed in international units (IU) is determined using the European Pharmacopoeial chromogenic assay against the WHO standard. The specific activity of ReFacto is 9110-13700 IU per milligram of protein. ReFacto is not purified from human blood and contains no preservatives or added human or animal components in the final formulation.
ReFacto is formulated as a sterile, nonpyrogenic, lyophilized powder preparation for intravenous (IV) injection. It is available in single-use vials containing the labeled amount of factor VIII activity (IU). Each vial contains nominally 250, 500, 1000 or 2000 IU of ReFacto per vial. The formulated product is a clear colorless solution upon reconstitution and contains sodium chloride, sucrose, L-histidine, calcium chloride, and polysorbate 80.
Last reviewed on RxList: 2/19/2009





Other reviews about Refacto on wordpress

Frankly Speaking
  by idotrcfc
Updated Mon., Oct. 1 2007*Frank Padilla's response at the bottom.This will be the start of another very interesting multi-part entry.I initially saw the questions posed to Frank in […]


NCC and Pfizer Partner to Provide 10 Million Units of Hemophilia Medicines
  by bleedingdisorder
source: PR Newswire RALEIGH, N.C., Feb. 23 /PRNewswire-USNewswire/ -- The National Cancer Coalition (NCC) is pleased to announce its recent collaboration with Pfizer, Inc to provide hemophilia medicines to […]


Baxter Analysis
  by jamesspada
I. Current Situation A. Current Performance Net Sales Baxter had a 2% increase over 2008 net sales, as the company brought in $12.6 billion during 2009.(Baxter, 2010(a)) US sales were […]


Advanced eclipse and Rational Team Concert (RTC) tips
  by danielwould
I spend pretty much most days working in and around RTC, and eclipse based tool for development and agile project development. Many of the great features are very […]


Wyeth - Products
  by El Horror
About - Merged with Pfizer in 2009. Financial advisors: Morgan Stanley and Evercore Partners. Legal advisor: Simpson Thacher & Bartlett LLP. - Wyeth Pharmaceuticals: 37 manufacturing facilities in 17 countries […]


Hemophilia - Drug Pipeline Analysis and Market Forecasts to 2016
  by reportsnreports
Dallas, TX: ReportsandReports announce it will 聽carry Hemophilia - Drug Pipeline Analysis and Market Forecasts to 2016,Market Research Report in its Store. Browse the complete Report on: http://www.reportsandreports.com/market-reports/hemophilia-drug-pipeline-analysis-and-market-forecasts-to-2016/ Hemophilia […]


Hemophilia - Drug Pipeline Analysis and Market Forecasts to 2016
  by reportsnreports
Dallas, TX: ReportsandReports announce it will 聽carry Hemophilia - Drug Pipeline Analysis and Market Forecasts to 2016,Market Research Report in its Store. Browse the complete Report on: http://www.reportsandreports.com/market-reports/hemophilia-drug-pipeline-analysis-and-market-forecasts-to-2016/ Hemophilia […]


New Report Hemophilia - Drug Pipeline Analysis and Market Forecasts to 2016 added by WorldMarketStudy
  by worldmarketstudy
WorldMarketStudy announces it Will Carry GlobalData鈥檚 Hemophilia - Drug Pipeline Analysis and Market Forecasts to 2016 June reports in its store. Browse complete report at http://www.worldmarketstudy.com/market-report/hemophilia-drug-pipeline-analysis-market-forecasts-2016-500.html GlobalData鈥檚 pharmaceutical and healthcare […]



Other reviews about Refacto on web:

ReFacto Antihemophilic Factor (Recombinant) is indicated for the control and prevention of hemorrhagic episodes and for surgical prophylaxis in patients with hemophilia A. ReFacto Antihemophilic Factor (Recombinant) | Wyeth.com


Learn about the prescription medication Refacto (Antihemophilic Factor), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Refacto (Antihemophilic Factor) Drug Information: Uses, Side ...


If you芒聙聶re using ReFacto 脗庐 Antihemophilic Factor (Recombinant), get to know XYNTHA 脗庐 Antihemophilic Factor (Recombinant), Plasma/Albumin-Free. XYNTHA is a recombinant factor VIII ... ReFacto


NOTICE. The following information is intended for use only by residents of the United States. Countries outside of the United States may have regulatory requirements or medical ... Wyeth.com


Wyeth is now a part of Pfizer Inc. The merger of local Wyeth and Pfizer entities may be pending in various jurisdictions and is subject to completion of various local legal and ... Refacto.eu > Home


Refacto patient information. Detailed drug information for the consumer, includes dosage, Refacto side effects and more. Refacto consumer information from Drugs.com


REFACTO (Antihemophilic Factor VIII) drug information for Congenital Factor VIII deficiency, Hemophilia A from MPR including side effects, drug interactions, dosing ... REFACTO (Antihemophilic Factor VIII) drug information from MPR


Physician reviewed Refacto (recombinant) patient information - includes Refacto description, dosage and directions. Refacto (recombinant) medical facts from Drugs.com


Antihemophilic factor is a naturally occurring protein in the blood that helps blood to clot. A lack of antihemophilic factor VIII is the cause of hemophilia A. Refacto Information - Drugs and Treatments - MedHelp


an脗路ti脗路he脗路mo脗路phil脗路ic factor (n t-h m-f l k, n t-) n. Abbr. AHF. A protein substance in blood plasma that participates in and is essential for the blood-clotting process. ReFacto - definition of ReFacto by the Free Online Dictionary ...





Featured Reviews

Reviews Ramipril Capsules

Altace Capsules Drug Description ALTACE (ramipril) Capsules USE IN PREGNANCY When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy...
Read More  |  Review This
Reviews Etonogestrel, Ethinyl Estradiol Vaginal Ring

NuvaRing Drug Description NUVARING® (etonogestrel/ethinyl estradiol) Vaginal Ring delivers 0.120 mg/0.015 mg per day Women should be counseled that this product does not protect against HIV infection (AIDS) and other sexually...
Read More  |  Review This
Reviews Iplex

Iplex Drug Description IPLEX™ (mecasermin rinfabate [rDNA origin]) Injection DRUG DESCRIPTION What are the possible side effects of mecasermin rinfabate (iPlex)? Stop using mecasermin rinfabate and get emergency medical help...
Read More  |  Review This
Reviews Estrace Vaginal Cream

Estrace Vaginal Cream Drug Description ESTRACE® CREAM (estradiol) Vaginal Cream, USP, 0.01% ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER Close clinical surveillance of all women taking estrogens is important. Adequate diagnostic...
Read More  |  Review This
Reviews Tofranil

Tofranil Drug Description Tofranil® (imipramine hydrochloride) Tablets USP (10 mg, 25 mg, and 50 mg) Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....